Biomarkers in Alzheimer’s Disease Analysis by Mass Spectrometry-Based Proteomics
Alzheimer’s disease (AD) is a common chronic and destructive disease. The early diagnosis of AD is difficult, thus the need for clinically applicable biomarkers development is growing rapidly. There are many methods to biomarker discovery and identification. In this review, we aim to summarize Mass...
Main Authors: | Yahui Liu, Hong Qing, Yulin Deng |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2014-05-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/15/5/7865 |
Similar Items
-
Proteomics and Mass Spectrometry for Cancer Biomarker Discovery
by: Ming Lu, et al.
Published: (2007-01-01) -
Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer
by: Joohyun Ryu, et al.
Published: (2021-05-01) -
Urine Proteomics in the Era of Mass Spectrometry
by: Ashley Beasley-Green
Published: (2016-11-01) -
Proteomics Landscape of Alzheimer’s Disease
by: Ankit P. Jain, et al.
Published: (2021-03-01) -
Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
by: Jakob M Bader, et al.
Published: (2020-06-01)